Stocktoria

Replimune Group, Inc. REPL

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-07-20 · LEI

Replimune Group, Inc. statistics & valuation

Market cap$960.3M
P / B5.8×
Return on equity-188.9%
Net cash$125.7M
Enterprise value USD$834.6M
Earnings yield EBIT/EV-38.3%
Return on capital-116.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
201820192020202120222023202420252026
Operating margin (%)
201820192020202120222023202420252026
Return on equity (%)
-22.40% -28.60% -16.20% -28.70% -31.40% -57.60% -59.50% -188.90% 201820192020202120222023202420252026
Shares outstanding
5.0M 31.7M 36.7M 46.6M 52.2M 58.2M 66.6M 80.6M 92.8M 201820192020202120222023202420252026
Net debt ($)
-$49.7M -$105.9M -$117.9M -$29.6M -$64.7M -$125.7M 201820192020202120222023202420252026
Share buybacks ($)
201820192020202120222023202420252026
Return on assets (%)
-30.20% -20.00% -22.50% -14.90% -25.60% -27.00% -44.20% -44.90% -94.40% 201820192020202120222023202420252026
Free cash flow margin (%)
201820192020202120222023202420252026
Debt / equity (×)
0.05× 0.00× 0.05× 0.12× 0.11× 0.50× 201820192020202120222023202420252026
EPS ($)
-$1.75 -$2.26 -$2.99 -$3.24 -$3.07 -$3.38 201820192020202120222023202420252026

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Return on assets-94.4%-44.9%-44.2%-27.0%-25.6%-14.9%-22.5%-20.0%-30.2%
Return on equity-188.9%-59.5%-57.6%-31.4%-28.7%-16.2%-28.6%-22.4%70.2%
Debt / equity0.50×0.11×0.12×0.05×0.00×—0.05×——
Current ratio4.797.9510.7217.5219.4633.2514.6814.2612.53

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.